A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...

A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...

v. 1. Histological classification of bone and joint tumors of domestic animals / compiled and reviewed by M.V. Slayter [and others] -- v. 2. Histological classification of mesenchymal tumors of skin ...

Neoadjuvant treatment with a programmed cell death 1 (PD-1) inhibitor induces clinical complete response and leads to organ preservation in a high proportion of patients with early-stage, mismatch ...

The cutting edge of treating solid tumors with cell therapies got notably sharper this year. As the director of Solid Tumor Cell Therapy and leader of Stanford Medicine’s Melanoma and Cutaneous ...

Today some of the most aggressive solid tumor cancers remain stubbornly resistant to treatment. There are many reasons why these cancers are difficult to treat, including mutations they may express or ...

Chimeric antigen receptor (CAR) T-cell therapy has had a transformational impact on the treatment of aggressive hematologic malignancies. The therapies have given life-extending options to patients ...

Mavrostobart targets CD73 to counteract immune suppression in the tumor microenvironment, maintaining efficacy at high concentrations without the "hook effect." The MORNINGSTAR trial evaluates ...

Pheast Therapeutics has begun a phase 1 trial for PHST001, targeting CD24 in advanced solid tumors, to evaluate safety and determine the phase 2 dose. PHST001 has shown promising preclinical results, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. It’s only the beginning. That common refrain echoed ...